Thyroid cancer affects over 40,000 people annually in the US and 20,000 people annually in Japan. While it generally has a favorable prognosis, treatment options for refractory cases are extremely limited. Standard treatment with sodium iodide requires a week-long hospital stay in a specialized radiation therapy ward, posing a significant burden on patients and leading to a waiting list due to ward shortages in Japan. αf-001, a trial drug utilizing the property of 211At to accumulate in the NIS, offers the potential for a new treatment with less patient burden and greater therapeutic effect. Currently, a Phase 1 trial is being conducted at Osaka University Hospital (NCT 05275946).


Watabe T, et al. Enhancement of 211At Uptake via the Sodium
Iodide Symporter by the Addition of Ascorbic Acid in Targeted
α-Therapy of Thyroid Cancer. J Nucl Med. 2019;60(9):1301-1307


Prostate cancer affects about 300,000 people annually in the US and is the most common new cancer among men in Japan (90,000 new cases/year in Japan). Hormonal therapy is administered for recurrent disease after surgery or radiotherapy, but the prognosis is poor for hormone-refractory prostate cancer (CRPC) with multiple metastases.
Recently, prostate-specific membrane antigen (PSMA), which is expressed in prostate cancer, has attracted much attention. We have successfully developed 211At-PSMA5, a new innovative therapeutic agent targeting PSMA. Evaluation using a prostate cancer model has confirmed marked hyperaccumulation in tumors and long-lasting tumor regression effects. 211At-PSMA5 is expected to enter clinical trials in the first half of 2024.

Watabe, Tadashi et al. “Targeted α-therapy using astatine
(211At)-labeled PSMA1, 5, and 6: a preclinical evaluation
as a novel compound.” European journal of nuclear medicine
and molecular imaging vol. 50,3 (2023): 849-858